Marco Guerrini - Search Results

Year	Number of Results
2002	7
2004	3
2005	3
2006	2
2007	4
2008	4
2009	5
2010	4
2011	3
2012	5
2013	8
2014	6
2015	2
2016	7
2017	6
2018	3
2019	6
2020	6
2021	6
2022	5
2023	3

1

Enisamium Inhibits SARS-CoV-2 RNA Synthesis.

Elli S, Bojkova D, Bechtel M, Vial T, Boltz D, Muzzio M, Peng X, Sala F, Cosentino C, Goy A, Guerrini M, Müller L, Cinatl J, Margitich V, Te Velthuis AJW. Elli S, et al. Among authors: guerrini m. Biomedicines. 2021 Sep 17;9(9):1254. doi: 10.3390/biomedicines9091254. Biomedicines. 2021. PMID: 34572438 Free PMC article.

2

Low-molecular-weight heparins: differential characterization/physical characterization.

Guerrini M, Bisio A. Guerrini M, et al. Handb Exp Pharmacol. 2012;(207):127-57. doi: 10.1007/978-3-642-23056-1_7. Handb Exp Pharmacol. 2012. PMID: 22566224 Review.

3

Fine structural characterization of sulodexide.

Veraldi N, Guerrini M, Urso E, Risi G, Bertini S, Bensi D, Bisio A. Veraldi N, et al. Among authors: guerrini m. J Pharm Biomed Anal. 2018 Jul 15;156:67-79. doi: 10.1016/j.jpba.2018.04.012. Epub 2018 Apr 15. J Pharm Biomed Anal. 2018. PMID: 29689470

4

Molecular Aspects of Heparanase Interaction with Heparan Sulfate, Heparin and Glycol Split Heparin.

Elli S, Guerrini M. Elli S, et al. Among authors: guerrini m. Adv Exp Med Biol. 2020;1221:169-188. doi: 10.1007/978-3-030-34521-1_6. Adv Exp Med Biol. 2020. PMID: 32274710 Review.

5

Dynamic properties of biologically active synthetic heparin-like hexasaccharides.

Angulo J, Hricovíni M, Gairi M, Guerrini M, de Paz JL, Ojeda R, Martín-Lomas M, Nieto PM. Angulo J, et al. Among authors: guerrini m. Glycobiology. 2005 Oct;15(10):1008-15. doi: 10.1093/glycob/cwi091. Epub 2005 Jun 15. Glycobiology. 2005. PMID: 15958415

6

[What role for transcatheter mitral valve replacement?].

De Marco F, Casenghi M, Garatti A, Guerrini M, Tusa M, Bedogni F. De Marco F, et al. Among authors: guerrini m. G Ital Cardiol (Rome). 2019 Apr;20(4 Suppl 1):20S-26S. doi: 10.1714/3146.31275. G Ital Cardiol (Rome). 2019. PMID: 30994630 Italian.

7

Multivariate analysis applied to complex biological medicines.

Rudd TR, Mauri L, Marinozzi M, Stancanelli E, Yates EA, Naggi A, Guerrini M. Rudd TR, et al. Among authors: guerrini m. Faraday Discuss. 2019 Aug 15;218(0):303-316. doi: 10.1039/c9fd00009g. Faraday Discuss. 2019. PMID: 31123736

8

Minimum FGF2 binding structural requirements of heparin and heparan sulfate oligosaccharides as determined by NMR spectroscopy.

Guglier S, Hricovíni M, Raman R, Polito L, Torri G, Casu B, Sasisekharan R, Guerrini M. Guglier S, et al. Among authors: guerrini m. Biochemistry. 2008 Dec 30;47(52):13862-9. doi: 10.1021/bi801007p. Biochemistry. 2008. PMID: 19117094

9

Introduction to the Molecules Special Edition Entitled 'Heparan Sulfate and Heparin: Challenges and Controversies': Some Outstanding Questions in Heparan Sulfate and Heparin Research.

Yates EA, Gallagher JT, Guerrini M. Yates EA, et al. Among authors: guerrini m. Molecules. 2019 Apr 10;24(7):1399. doi: 10.3390/molecules24071399. Molecules. 2019. PMID: 30974725 Free PMC article.

10

Interaction of heparins with fibroblast growth factors: conformational aspects.

Guerrini M, Hricovíni M, Torri G. Guerrini M, et al. Curr Pharm Des. 2007;13(20):2045-56. doi: 10.2174/138161207781039733. Curr Pharm Des. 2007. PMID: 17627538 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results